



Contact:
Tiana DiMichele
Trimel Pharmaceuticals
tdimichele@trimelpharmaceuticals.com
(416) 679-0822

TRIMEL TO PRESENT AT THE JMP SECURITIES LIFE SCIENCES CONFERENCE 2015

Toronto, Canada, June 8, 2015 – Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that management is scheduled to present an overview of the Company at the JMP Securities Life Sciences Conference 2015 at the St. Regis New York on June 24, 2015 at 2:30 p.m. Eastern Time.

The JMP Securities' annual life sciences equity research conference is an institutional investor forum featuring publicly traded and privately held companies in the areas of biotechnology, specialty pharmaceuticals, medical devices, life science tools and diagnostics.

About Trimel

Trimel is a Canadian pharmaceutical company focused on the development and marketing of innovative products that improve the patient experience and produce strong investor returns.

Trimel markets ESTRACE[®] in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO[™], a product utilizing Trimel's licensed nasal gel technology, is the first testosterone nasal gel filed in Canada for approval, and is the first and only testosterone nasal gel approved and launched in the United States for replacement therapy in adult males diagnosed with hypogonadism. The commercial rights to NATESTO[™] in the United States and Mexico have been licensed by Trimel to an affiliate of Endo International plc. TEFINA[™], a "use as required" nasal testosterone gel, is Trimel's drug development candidate aimed at addressing a significant unmet need for women with anorgasmia.

For more information, please visit www.trimelpharmaceuticals.com.

#